AbbVie (NYSE: ABBV) announced today that it has completed its acquisition of Aliada Therapeutics. With the completion of the acquisition, Aliada is now a part of AbbVie.
AbbVie has completed its acquisition of Aliada Therapeutics which includes Aliada’s disease-modifying therapy for Alzheimer’s disease.
10h
RA Capital Management, LP (RA Capital), a multi-stage investment manager dedicated to evidence-based investing in public and private healthcare, life sciences, and planetary health companies, today ...
Saskatchewan Blue Cross, a leading health and wellness solutions provider, is dedicated to making a meaningful difference in ...
Power Lifetm by Tony Horton, the premium supplement brand designed to fuel active, healthy living, is celebrating its 5th anniversary. Since its launch in 2020, Power Life has become a game changer in ...
The North Chicago-based drugmaker said it's received positive topline results in a Phase 3 trial of its investigational ...
GSK, Gilead and Arcellx, Vertex and more present new data at the American Society of Hematology annual meeting just as sickle cell therapies Casgevy and Lyfgenia have a new outcomes-based payment ...
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Good morning, hope everyone is ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback